Browsing by Author de Azambuja, E

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 4 of 4
TitleAuthor(s)Issue Date
 
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Journal:The Lancet
Goldhirsch, AGelber, RDPiccart-Gebhart, MJde Azambuja, EProcter, MSuter, TMJackisch, CCameron, DWeber, HAHeinzmann, DLago, LDMcFadden, EDowsett, MUntch, MGianni, LBell, RKöhne, CHVindevoghel, AAndersson, MBrunt, AMOtero-Reyes, DSong, SSmith, ILeyland-Jones, BBaselga, JKwong, A
2013
 
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Journal:The New England Journal of Medicine
von Minckwitz, GProcter, Mde Azambuja, EZardavas, DBenyunes, MKwong, APiccart, MBaselga, J
2017
 
Estimating The Magnitude Of Trastuzumab Effects Within Patient Subgroups In The Hera Trial
Journal:Annals of Oncology
Untch, MGelber, RDJackisch, CProcter, MBaselga, JBell, RCameron, DBari, MSmith, ILeyland-Jones, Bde Azambuja, EWermuth, PKhasanov, RFeng-yi, FConstantin, CMayordomo, JISu, CHYu, SYLluch, ASenkus-Konefka, EPrice, CHaslbauer, FSahui, TSSrimuninnimit, VColleoni, MCoates, ASPiccart-Gebhart, MJGoldhirsch, AKwong, A
2008
 
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Journal:Lancet
Baselga, JBradbury, IEidtmann, HDi Cosimo, Sde Azambuja, EAura, CGomez, HDinh, PFauria, KVan Dooren, VAktan, GGoldhirsch, AChang, TWHorvath, ZCoccia-Portugal, MDomont, JTseng, LMKunz, GSohn, JHSemiglazov, VLerzo, GPalacova, MProbachai, VPusztai, LUntch, MGelber, RDPiccart-Gebhart, MNeoALTTO Study Team,Kwong, A
2012
Showing results 1 to 4 of 4